About Tenpoint Therapeutics
Tenpoint Therapeutics is a company based in Cambridge (United Kingdom) founded in 2020 by Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, and Deniz Dalkara. It operates as a HealthTech. Tenpoint Therapeutics has raised $155 million across 4 funding rounds from investors including Eight Roads Ventures, UCL Technology Fund and British Patient Capital. Tenpoint Therapeutics offers products and services including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment. Tenpoint Therapeutics operates in a competitive market with competitors including Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
- Headquarter Cambridge, United Kingdom
- Founders Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, Deniz Dalkara
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tenpoint Therapeutics, Ltd.
-
Annual Revenue
-
Net Profit
-$12.25 M (USD)-131as on Dec 31, 2022
-
EBITDA
-$13.27 M (USD)-136as on Dec 31, 2022
-
Total Equity Funding
$155 M (USD)
in 4 rounds
-
Latest Funding Round
$150 M (USD), Debt – Conventional
Jan 29, 2026
-
Investors
Eight Roads Ventures
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tenpoint Therapeutics
Tenpoint Therapeutics offers a comprehensive portfolio of products and services, including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Developed for treating presbyopia in aging eyes.
Formulated to address cataracts in aging patients.
Designed to treat geographic atrophy in eyes.
People of Tenpoint Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Tenpoint Therapeutics
Tenpoint Therapeutics has successfully raised a total of $155M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $150 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Conventional — $150.0M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series B - Tenpoint Therapeutics | Valuation | Janus Henderson Investors , EQT | |
| Jan, 2026 | Amount | Debt – Conventional - Tenpoint Therapeutics | Valuation |
investors |
|
| Jul, 2023 | Amount | Series A - Tenpoint Therapeutics | Valuation | British Patient Capital , F-Prime Capital |
Investors in Tenpoint Therapeutics
Tenpoint Therapeutics has secured backing from 11 investors, including venture fund investors. Prominent investors backing the company include Eight Roads Ventures, UCL Technology Fund and British Patient Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital co-investments are made in UK later-stage businesses.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tenpoint Therapeutics
Financial Statements - Tenpoint Therapeutics
Tenpoint Therapeutics Comparisons
Competitors of Tenpoint Therapeutics
Tenpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of drug discovery and preclinical development services
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Data analysis and statistical solutions are provided for life sciences.
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Provider of laboratory tests for physicians
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
Latest news on Tenpoint Therapeutics
Frequently Asked Questions about Tenpoint Therapeutics
Tenpoint Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Tenpoint Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Eddy Anglade is the current CEO of Tenpoint Therapeutics.
Tenpoint Therapeutics is a funded company, having raised a total of $155M across 4 funding rounds to date. The company's 1st funding round was a Series A of $70M, raised on Jun 01, 2021.
Tenpoint Therapeutics is dedicated to pioneering treatments for rejuvenating vision in aging eyes. The company targets major ophthalmic indications such as presbyopia, cataracts, and geographic atrophy. Innovative solutions are being developed to address the largest unmet needs in eye care, with a pipeline aimed at transforming treatment paradigms. Operations span across multiple global locations to support research and development in the healthcare sector.
Tenpoint Therapeutics's top competitors include LabCorp, Annexon and Charles River Laboratories.
Tenpoint Therapeutics offers Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Tenpoint Therapeutics has 11 investors. Key investors include Eight Roads Ventures, UCL Technology Fund, British Patient Capital, F-Prime Capital, and Sofinnova Partners.